🚨 Don't miss the latest from OncoAlert! 📰
✅ U.S. FDA gives green light to trastuzumab dx 🇺🇸 ✅ Impact of Durvalumab on small cell lung cancer 🫁 ✅ ALINA study results in #NSCLC on NEJM
Plus, CD70 CART in #KidneyCancer , Adagrasib Cetux 💊 in #ColorectalCancer , and more…

💊Second line treatment of advanced gastric/GEJ cancer:
FOLFIRI plus durvalumab-tremelimumab vs. FOLFIRI plus durvalumab
JAMA Oncology

❌The primary end point (PFS at 4 months) was not met. (44.7% vs 55.6%)

➡️Phase 2, 96 patients
➡️No previous IO in the first line
➡️mPFS: 3.8 vs…

Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial. #lcsm #oncology onclive.com/view/consolida…

BIG NEWS press release by AstraZeneca! - Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

oncodaily.com/45454.html

#oncodaily #oncology #cancer #AstraZeneca #ADRIATICtrial #Durvalumab #SmallCellLungCancer #OncologyNews #ClinicalTrialsSuccess

Consolidation therapy with durvalumab improve OS and PFS compared with placebo in patients with limited stage SCLC who had not progressed following concurrent chemoradiotherapy. #lcsm #oncology onclive.com/view/consolida…

⚡️ CALLA trial on durvalumab in cervical cancer + RT! 🩺 No significant difference in progression-free survival observed, but potential for further exploration in high tumoral PD-L1 expression patients.

thelancet.com/journals/lanon…

#CALLATrial #CervicalCancer 🌍

The OncoAlert 🚨Newsletter is Out
Covering April 5th-12th, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Discussing:
✅ U.S. FDA approval trastuzumab dx🇺🇸
✅Durvalumab in Small Cell #LungCancer 🫁
✅ALINA 🫁 #NSCLC out on NEJM
✅CD70 CART in…

Durvalumab versus placebo with chemoradiotherapy for locally advanced #cervicalcancer (CALLA): a randomised, double-blind, phase 3 trial published in The Lancet Oncology.
👉 Read it before your patients in the #ESTRONewsletter : bit.ly/3wVnSxX

Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study onlinelibrary.wiley.com/doi/10.1002/he…

Dr. Josep Llovet Icahn School of Medicine at Mount Sinai provides expert perspective in The ASCO Post
For Unresectable Liver Cancer, the Addition of Durvalumab and Bevacizumab Boosts Efficacy of Transarterial Chemoembolization
bit.ly/4aRwWTf

News—
Durvalumab Significantly Benefits #SCLC Patients.
bit.ly/3J9FIA8

Huge News!!! Press release for OS and PFS benefit from durvalumab after chemorads in ls-sclc. Awaiting data from ph III ADRIATIC study. Lets gooo #lcsm LungCancerRx 🫁💊 Hem-Onc Fellows Network #FlorezLab OncoAlert

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC. #kcsm #oncology onclive.com/view/durvaluma…

ADRIATIC trial of durvalumab elicits statistically significant OS and PFS in limited-stage #SCLC .

cancernetwork.com/view/durvaluma…

The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival—when compared to TACE alone—among patients with unresectable hepatocellular carcinoma who are eligible for #embolization . Keep reading: ow.ly/5ox150Rchl6 #HCC

Imfinzi (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - AstraZeneca medicalupdateonline.com/2024/04/imfinz…

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma jamanetwork.com/journals/jamao…

Durvalumab plus trastuzumab and pertuzumab produced a high pathologic response rate in a phase 2 trial of patients with HER2-enriched early breast cancer. Results were presented at #AACR24 by Dr Jian Guan from Houston Methodist MD. #bcsm cancertherapyadvisor.com/reports/chemo-…

Phase III #ADRIATIC #Trial : #Immunotherapy #Durvalumab vs Placebo in Limited Stage #SCLC , reported meeting both #OS & #PFS endpoints, offering hope for improved treatment #lungcancer

‼️ GAME-CHANGING for our patients with limited-stage small cell lung cancer

Phase 3 ADRIATIC study of durvalumab after chemoradiation for patients w/ limited-stage SCLC

✅ OS benefit
✅ PFS benefit

Eager to review the full results OncoAlert #lcsm